Abstract:<p>With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies were included, with a population of 2,054,554 from 28 provinces and districts. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle‐aged, males, those in northwest China and Taiwan, regions with a gross domestic product (GDP) per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease (CVD) and metabolic syndrome (MetS). The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared to their proportion of the NAFLD population in such trials.</p><h3> Conclusion</h3><p>China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.</p><p>This article is protected by copyright. All rights reserved.</p><p>With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies were included, with a population of 2,054,554 from 28 provinces and districts. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle‐aged, males, those in northwest China and Taiwan, regions with a gross domestic product (GDP) per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease (CVD) and metabolic syndrome (MetS). The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared to their proportion of the NAFLD population in such trials.</p><h3> Conclusion</h3><p>China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.</p><p>This article is protected by copyright. All rights reserved.</p>

Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.

General Characteristics and Clinical Practices of Chinese Patients with Non-Alcoholic Fatty Liver Disease

Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (version 2024)

Prevalence and Risk Factors for the Development of Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: the Zhejiang Zhenhai Study.

Clinical guidelines of non-alcoholic fatty liver disease: A systematic review.

An interpretation of European guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease

Epidemiological Characteristics and Management of Nonalcoholic Fatty Liver Disease/nonalcoholic Steatohepatitis in China: A Narrative Review

Relationship Between Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.

[An Interpretation of the AASLD Practice Guideline on the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in 2017].

Epidemiology of alcoholic and nonalcoholic fatty liver disease in China

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease

The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease

Role of diet and nutritional management in non-alcoholic fatty liver disease

Management of Non-Alcoholic Fatty Liver Disease: Lifestyle Changes.

2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

Position statement on the diagnosis and management of non-alcoholic fatty liver disease

MAFLD Vs. NAFLD: Shared Features and Potential Changes in Epidemiology, Pathophysiology, Diagnosis, and Pharmacotherapy

Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease in children and adults in China and for-eign countries:comparison and analysis